Ridaq-25 & Ridaq-50 25 mg /50 mg Tablet
PDF Leaflet Revision Date: 04 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Oedema and essential hypertension.
Dosage (summary)
Adults: 25-100 mg daily; may start with 200 mg for some cases.
Onset of Action / Duration
Onset: 2 hours, Duration: 12 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy (especially 2nd/3rd trimester) or lactation.
Key Drug Interactions
- Antidiabetic medicines
- Digitalis glycosides
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity to hydrochlorothiazide
- Anuria
- Severe renal impairment
- Severe hepatic impairment
- Addisonu2019s disease
- Hypercalcaemia
Common side effects
- Hypokalaemia
- Hyponatraemia
- Dizziness
- Nausea
- Photosensitivity
Counselling Points
- Monitor for electrolyte imbalances
- Avoid sun exposure
- Report any skin changes
Serious warnings
- Risk of non-melanoma skin cancer
- Electrolyte imbalance
- Acute angle-closure glaucoma
Important Disclaimer
The Ridaq-25 & Ridaq-50 25 mg /50 mg Tablet professional information leaflet below is the property of Pharmacare Ltd and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
